Cochrane · systematic review · CD009745
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion
Simancas‐Racines, D, Osorio, D, Martí‐Carvajal, AJ, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
InjuriesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
4
No studies
1
Included studies
NR
No studies 1 · 20%Ungraded 0 · 0%Very low 2 · 40%Low 2 · 40%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Leukoreduced PRBCs versus non‐leukoreduced PRBCs for preventing adverse reaction from allogeneic blood transfusion
Population: Patients receiving RBC transfusion
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
TRALI Leukoreduced PRBCs vs non‐leukoreduced PRBCs | RR 0.96 [0.67, 1.36] | 1 study · 1864 participants | Low Downgraded: imprecision |
Death due to any cause Leukoreduced PRBCs vs non‐leukoreduced PRBCs | RR 0.81 [0.58, 1.12] | 9 studies · 6485 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Infection from any cause Leukoreduced PRBCs vs non‐leukoreduced PRBCs | RR 0.8 [0.62, 1.03] | 10 studies · 6709 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events Leukoreduced PRBCs vs non‐leukoreduced PRBCs | RR 0.81 [0.64, 1.02] | 2 studies · 634 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Non‐infectious complication Leukoreduced PRBCs vs non‐leukoreduced PRBCs | no estimate extracted | NR | No studies |